Lung cancer has seen a paradigm shift in disease treatment over the
past few years, with major changes in the therapeutic drugs now
available as well as in the overall management approach. For
targeted and immunotherapeutic approaches, understanding the
biology of acquired resistance is a key strategy that has yielded
productive advances in the subsequent treatment. Future advances
also include incorporating biomarker data obtained from solid and
liquid biopsies, as well as combination of immunotherapy with
radiotherapy and in special populations such patients with CNS
involvement.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!